Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial

Jeff S. Coombes; Katrin A. Dias; Ravin Lal; Robert G. Fassett; Matthew P. Wallen; Joyce S. Ramos; Suzanna Russell; Natalie K. Vear; Trishan Gajanand; Tom G. Bailey; Daniel J. Green; Brooke K. Coombes; Llion A. Roberts

doi:10.1016/j.diabres.2023.110701

Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial

Jeff S. Coombes, Katrin A. Dias, Ravin Lal, Robert G. Fassett, Matthew P. Wallen, Joyce S. Ramos, Suzanna Russell, Natalie K. Vear, Trishan Gajanand, Tom G. Bailey, Daniel J. Green, Brooke K. Coombes, Llion A. Roberts

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Aims: To determine the efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus (T2D), and any persistent benefits 7 weeks following treatment.

Methods: 50 participants with T2D were randomly assigned to either 1) 20x45-minute ECP sessions over 7 weeks (ECP₄₅), 2) 20x30-minute ECP sessions over 7 weeks (ECP₃₀) or 3) SHAM control. Outcomes were assessed at baseline, after 7 weeks of the intervention and 7 weeks after the interventions finished. Efficacy was determined from changes in HbA_1c.

Results: After 7 weeks, there were significant between-group differences, with ECP₄₅ lowering HbA_1c compared to SHAM (mean [95% CI] −0.7 [-0.1 to −1.3] %; −7 [-1 to −15] mmol/mol). Within group changes were; ECP₄₅ (mean ± SD −0.8 ± 0.8%; −8 ± 8 mmol/mol), ECP₃₀ (-0.2 ± 0.5%; −2 ± 6 mmol/mol) and SHAM (-0.1 ± 0.9%; −1 ± 10 mmol/mol). HbA_1c in the ECP₄₅ group remained lower 7 weeks after completing the intervention; ECP₄₅ (7.0 ± 1.1%; 53 ± 26 mmol/mol), ECP₃₀ (7.7 ± 1.4%; 60 ± 16 mmol/mol) and SHAM (7.7 ± 1.0%; 60 ± 10 mmol/mol).

Conclusions: In people with T2D, ECP₄₅ for 7 weeks improved glycemic control when compared to ECP₃₀ and a SHAM control group.

Original language	English
Article number	110701
Number of pages	9
Journal	Diabetes Research and Clinical Practice
Volume	200
Early online date	10 May 2023
DOIs	https://doi.org/10.1016/j.diabres.2023.110701
Publication status	Published - Jun 2023
Externally published	Yes

Keywords

Basal disposition index
Beta cell function
HbA
Insulin resistance Insulin resistance
Insulin sensitivity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.diabres.2023.110701Licence: In Copyright

Cite this

Coombes, J. S., Dias, K. A., Lal, R., Fassett, R. G., Wallen, M. P., Ramos, J. S., Russell, S., Vear, N. K., Gajanand, T., Bailey, T. G., Green, D. J., Coombes, B. K., & Roberts, L. A. (2023). Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial. Diabetes Research and Clinical Practice, 200, Article 110701. https://doi.org/10.1016/j.diabres.2023.110701

@article{d87b5056c8d042a28bcebb2ba8d57ffd,

title = "Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial",

abstract = "Aims: To determine the efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus (T2D), and any persistent benefits 7 weeks following treatment. Methods: 50 participants with T2D were randomly assigned to either 1) 20x45-minute ECP sessions over 7 weeks (ECP45), 2) 20x30-minute ECP sessions over 7 weeks (ECP30) or 3) SHAM control. Outcomes were assessed at baseline, after 7 weeks of the intervention and 7 weeks after the interventions finished. Efficacy was determined from changes in HbA1c. Results: After 7 weeks, there were significant between-group differences, with ECP45 lowering HbA1c compared to SHAM (mean [95% CI] −0.7 [-0.1 to −1.3] %; −7 [-1 to −15] mmol/mol). Within group changes were; ECP45 (mean ± SD −0.8 ± 0.8%; −8 ± 8 mmol/mol), ECP30 (-0.2 ± 0.5%; −2 ± 6 mmol/mol) and SHAM (-0.1 ± 0.9%; −1 ± 10 mmol/mol). HbA1c in the ECP45 group remained lower 7 weeks after completing the intervention; ECP45 (7.0 ± 1.1%; 53 ± 26 mmol/mol), ECP30 (7.7 ± 1.4%; 60 ± 16 mmol/mol) and SHAM (7.7 ± 1.0%; 60 ± 10 mmol/mol). Conclusions: In people with T2D, ECP45 for 7 weeks improved glycemic control when compared to ECP30 and a SHAM control group.",

keywords = "Basal disposition index, Beta cell function, HbA, Insulin resistance Insulin resistance, Insulin sensitivity",

author = "Coombes, {Jeff S.} and Dias, {Katrin A.} and Ravin Lal and Fassett, {Robert G.} and Wallen, {Matthew P.} and Ramos, {Joyce S.} and Suzanna Russell and Vear, {Natalie K.} and Trishan Gajanand and Bailey, {Tom G.} and Green, {Daniel J.} and Coombes, {Brooke K.} and Roberts, {Llion A.}",

year = "2023",

month = jun,

doi = "10.1016/j.diabres.2023.110701",

language = "English",

volume = "200",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Health Sciences",

}

Coombes, JS, Dias, KA, Lal, R, Fassett, RG, Wallen, MP , Ramos, JS, Russell, S, Vear, NK, Gajanand, T, Bailey, TG, Green, DJ, Coombes, BK & Roberts, LA 2023, 'Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial', Diabetes Research and Clinical Practice, vol. 200, 110701. https://doi.org/10.1016/j.diabres.2023.110701

TY - JOUR

T1 - Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus

T2 - A randomized SHAM-controlled trial

AU - Coombes, Jeff S.

AU - Dias, Katrin A.

AU - Lal, Ravin

AU - Fassett, Robert G.

AU - Wallen, Matthew P.

AU - Ramos, Joyce S.

AU - Russell, Suzanna

AU - Vear, Natalie K.

AU - Gajanand, Trishan

AU - Bailey, Tom G.

AU - Green, Daniel J.

AU - Coombes, Brooke K.

AU - Roberts, Llion A.

PY - 2023/6

Y1 - 2023/6

N2 - Aims: To determine the efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus (T2D), and any persistent benefits 7 weeks following treatment. Methods: 50 participants with T2D were randomly assigned to either 1) 20x45-minute ECP sessions over 7 weeks (ECP45), 2) 20x30-minute ECP sessions over 7 weeks (ECP30) or 3) SHAM control. Outcomes were assessed at baseline, after 7 weeks of the intervention and 7 weeks after the interventions finished. Efficacy was determined from changes in HbA1c. Results: After 7 weeks, there were significant between-group differences, with ECP45 lowering HbA1c compared to SHAM (mean [95% CI] −0.7 [-0.1 to −1.3] %; −7 [-1 to −15] mmol/mol). Within group changes were; ECP45 (mean ± SD −0.8 ± 0.8%; −8 ± 8 mmol/mol), ECP30 (-0.2 ± 0.5%; −2 ± 6 mmol/mol) and SHAM (-0.1 ± 0.9%; −1 ± 10 mmol/mol). HbA1c in the ECP45 group remained lower 7 weeks after completing the intervention; ECP45 (7.0 ± 1.1%; 53 ± 26 mmol/mol), ECP30 (7.7 ± 1.4%; 60 ± 16 mmol/mol) and SHAM (7.7 ± 1.0%; 60 ± 10 mmol/mol). Conclusions: In people with T2D, ECP45 for 7 weeks improved glycemic control when compared to ECP30 and a SHAM control group.

AB - Aims: To determine the efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus (T2D), and any persistent benefits 7 weeks following treatment. Methods: 50 participants with T2D were randomly assigned to either 1) 20x45-minute ECP sessions over 7 weeks (ECP45), 2) 20x30-minute ECP sessions over 7 weeks (ECP30) or 3) SHAM control. Outcomes were assessed at baseline, after 7 weeks of the intervention and 7 weeks after the interventions finished. Efficacy was determined from changes in HbA1c. Results: After 7 weeks, there were significant between-group differences, with ECP45 lowering HbA1c compared to SHAM (mean [95% CI] −0.7 [-0.1 to −1.3] %; −7 [-1 to −15] mmol/mol). Within group changes were; ECP45 (mean ± SD −0.8 ± 0.8%; −8 ± 8 mmol/mol), ECP30 (-0.2 ± 0.5%; −2 ± 6 mmol/mol) and SHAM (-0.1 ± 0.9%; −1 ± 10 mmol/mol). HbA1c in the ECP45 group remained lower 7 weeks after completing the intervention; ECP45 (7.0 ± 1.1%; 53 ± 26 mmol/mol), ECP30 (7.7 ± 1.4%; 60 ± 16 mmol/mol) and SHAM (7.7 ± 1.0%; 60 ± 10 mmol/mol). Conclusions: In people with T2D, ECP45 for 7 weeks improved glycemic control when compared to ECP30 and a SHAM control group.

KW - Basal disposition index

KW - Beta cell function

KW - HbA

KW - Insulin resistance Insulin resistance

KW - Insulin sensitivity

UR - http://www.scopus.com/inward/record.url?scp=85159602549&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2023.110701

DO - 10.1016/j.diabres.2023.110701

M3 - Article

C2 - 37172647

AN - SCOPUS:85159602549

SN - 0168-8227

VL - 200

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

M1 - 110701

ER -

Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this